JPH10507752A - 血管増殖性疾患処置用ポリアミン化合物 - Google Patents

血管増殖性疾患処置用ポリアミン化合物

Info

Publication number: JPH10507752A
Authority: JP; Japan
Prior art keywords: vascular proliferative; polyamine; restenosis; compound; alkyl
Prior art date: 1994-10-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

JP8513897A

Other languages

English (en)

Japanese (ja)

Inventor

ヒユーペ，ドナルド

カイザー，ジヨーン・アレツクシス

Original Assignee

ワーナー−ランバート・コンパニー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-25

Filing date

1995-09-14

Publication date

1998-07-28

1995-09-14 Application filed by ワーナー−ランバート・コンパニー filed Critical ワーナー−ランバート・コンパニー

1998-07-28 Publication of JPH10507752A publication Critical patent/JPH10507752A/ja

Status Ceased legal-status Critical Current

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 22
230000002062 proliferating effect Effects 0.000 title claims abstract description 20
230000002792 vascular Effects 0.000 title claims abstract description 19
150000001875 compounds Chemical class 0.000 title claims description 21
201000010099 disease Diseases 0.000 title claims description 10
229920000768 polyamine Polymers 0.000 title abstract description 36
208000037803 restenosis Diseases 0.000 claims abstract description 21
238000002399 angioplasty Methods 0.000 claims abstract description 11
238000000034 method Methods 0.000 claims description 25
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
125000000217 alkyl group Chemical group 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 4
238000002054 transplantation Methods 0.000 claims description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
230000035755 proliferation Effects 0.000 abstract description 4
210000002464 muscle smooth vascular Anatomy 0.000 abstract description 2
208000035475 disorder Diseases 0.000 description 10
210000004027 cell Anatomy 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
241000700159 Rattus Species 0.000 description 8
241001465754 Metazoa Species 0.000 description 6
-1 when n = 4 Chemical compound 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
208000027418 Wounds and injury Diseases 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
210000001715 carotid artery Anatomy 0.000 description 5
230000004663 cell proliferation Effects 0.000 description 5
239000012091 fetal bovine serum Substances 0.000 description 5
208000014674 injury Diseases 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
230000001028 anti-proliverative effect Effects 0.000 description 4
210000001367 artery Anatomy 0.000 description 4
230000017531 blood circulation Effects 0.000 description 4
230000006378 damage Effects 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
210000000269 carotid artery external Anatomy 0.000 description 3
238000007887 coronary angioplasty Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
102100034274 Diamine acetyltransferase 1 Human genes 0.000 description 2
101710086762 Diamine acetyltransferase 1 Proteins 0.000 description 2
208000031481 Pathologic Constriction Diseases 0.000 description 2
239000005700 Putrescine Substances 0.000 description 2
101710181456 Spermidine N(1)-acetyltransferase Proteins 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004004 carotid artery internal Anatomy 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000013156 embolectomy Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000003902 lesion Effects 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
210000000329 smooth muscle myocyte Anatomy 0.000 description 2
239000000243 solution Substances 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
229940063673 spermidine Drugs 0.000 description 2
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
208000037804 stenosis Diseases 0.000 description 2
230000036262 stenosis Effects 0.000 description 2
229940124530 sulfonamide Drugs 0.000 description 2
150000003456 sulfonamides Chemical class 0.000 description 2
UODZHRGDSPLRMD-UHFFFAOYSA-N sym-homospermidine Chemical compound NCCCCNCCCCN UODZHRGDSPLRMD-UHFFFAOYSA-N 0.000 description 2
238000012360 testing method Methods 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
239000001993 wax Substances 0.000 description 2
BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
108700016155 Acyl transferases Proteins 0.000 description 1
102000057234 Acyl transferases Human genes 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010011086 Coronary artery occlusion Diseases 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
RPSHOHKFHRFBAZ-UHFFFAOYSA-N Homospermine Natural products NCCCCNCCCCNCCCCN RPSHOHKFHRFBAZ-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
PGMIWVSHZMWSSI-UHFFFAOYSA-N N(1),N(12)-diethylspermine Chemical compound CCNCCCNCCCCNCCCNCC PGMIWVSHZMWSSI-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
102000052812 Ornithine decarboxylases Human genes 0.000 description 1
108700005126 Ornithine decarboxylases Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000002682 anti-psoriatic effect Effects 0.000 description 1
230000000798 anti-retroviral effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
210000002376 aorta thoracic Anatomy 0.000 description 1
210000003433 aortic smooth muscle cell Anatomy 0.000 description 1
229920006167 biodegradable resin Polymers 0.000 description 1
OTBHHUPVCYLGQO-UHFFFAOYSA-N bis(3-aminopropyl)amine Chemical compound NCCCNCCCN OTBHHUPVCYLGQO-UHFFFAOYSA-N 0.000 description 1
230000005907 cancer growth Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000001168 carotid artery common Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000004087 circulation Effects 0.000 description 1
239000012059 conventional drug carrier Substances 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000003511 endothelial effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
229940042472 mineral oil Drugs 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
UMJJGDUYVQCBMC-UHFFFAOYSA-N n-ethyl-n'-[3-[3-(ethylamino)propylamino]propyl]propane-1,3-diamine Chemical compound CCNCCCNCCCNCCCNCC UMJJGDUYVQCBMC-UHFFFAOYSA-N 0.000 description 1
QXOCYGPVDXDFLC-UHFFFAOYSA-N n-ethyl-n'-[4-[4-(ethylamino)butylamino]butyl]butane-1,4-diamine Chemical compound CCNCCCCNCCCCNCCCCNCC QXOCYGPVDXDFLC-UHFFFAOYSA-N 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000002952 polymeric resin Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229940063675 spermine Drugs 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960000580 terconazole Drugs 0.000 description 1
230000002885 thrombogenetic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
230000003074 vasoproliferative effect Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

JP8513897A 1994-10-25 1995-09-14 血管増殖性疾患処置用ポリアミン化合物 Ceased JPH10507752A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/329,588 US5516807A (en)	1994-10-25	1994-10-25	Method for treating vascular proliferative disorders following balloon angioplasty
US08/329,588		1994-10-25
PCT/US1995/011680 WO1996012480A1 (en)	1994-10-25	1995-09-14	Polyamine compounds for treating vascular proliferative disorders

Publications (1)

Publication Number	Publication Date
JPH10507752A true JPH10507752A (ja)	1998-07-28

Family

ID=23286110

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP8513897A Ceased JPH10507752A (ja)	1994-10-25	1995-09-14	血管増殖性疾患処置用ポリアミン化合物

Country Status (12)

Country	Link
US (1)	US5516807A (de)
EP (1)	EP0786991B1 (de)
JP (1)	JPH10507752A (de)
AT (1)	ATE198706T1 (de)
CA (1)	CA2198914A1 (de)
DE (1)	DE69519937T2 (de)
DK (1)	DK0786991T3 (de)
ES (1)	ES2155531T3 (de)
GR (1)	GR3035725T3 (de)
MX (1)	MX9701838A (de)
PT (1)	PT786991E (de)
WO (1)	WO1996012480A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6515009B1 (en)	1991-09-27	2003-02-04	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en)	1993-01-28	1998-09-22	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en)	1993-01-28	1998-06-23	Neorx Corporation	Prevention and treatment of cardiovascular pathologies
US6251920B1 (en)	1993-05-13	2001-06-26	Neorx Corporation	Prevention and treatment of cardiovascular pathologies
US6306421B1 (en)	1992-09-25	2001-10-23	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en)	1993-01-28	2003-12-16	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en)	1993-01-28	1999-11-09	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en)	1993-05-13	2002-12-10	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US7611533B2 (en) *	1995-06-07	2009-11-03	Cook Incorporated	Coated implantable medical device
CA2223595C (en) *	1995-06-07	2008-08-05	Neorx Corporation	Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
CA2264745C (en) *	1996-09-13	2003-11-11	University Of Florida Research Foundation, Inc.	Method of inhibiting biosynthesis of eif5a
US6083991A (en) *	1997-06-04	2000-07-04	University Of Florida Research Foundation, Inc.	Anti-arrhythmic composition and methods of treatment
US7087648B1 (en)	1997-10-27	2006-08-08	The Regents Of The University Of California	Methods for modulating macrophage proliferation using polyamine analogs
US8198334B2 (en) *	1997-10-27	2012-06-12	Pathologica Llc	Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
DE60029944T2 (de)	1999-04-30	2007-04-05	Cellgate, Inc., Redwood City	Polyamine und ihre therapeutische verwendung
US6649587B1 (en)	1999-04-30	2003-11-18	Slil Biomedical Corporation	Polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US6482943B1 (en) *	1999-04-30	2002-11-19	Slil Biomedical Corporation	Quinones as disease therapies
IL146126A0 (en) *	1999-04-30	2002-07-25	Slil Biomedical Corp	Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
US7312244B2 (en) *	1999-04-30	2007-12-25	Cellgate, Inc.	Polyamine analog-amino acid conjugates useful as anticancer agents
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
CA2469354A1 (en) *	2001-12-07	2003-06-19	Slil Biomedical Corporation	Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor
JP2004189714A (ja) *	2002-12-09	2004-07-08	Rasanen Tiina-Liisa	すい臓炎の治療と予防ならびに肝臓再生機能の誘導のための薬剤
BRPI0517551A (pt) *	2004-10-04	2008-10-14	Cellgate Inc	análogos de poliamina como agentes terapêuticos para doenças oculares
US20070232677A1 (en) *	2006-03-14	2007-10-04	Marton Laurence J	Treatment and prevention of vascular hyperplasia using polyamine and polyamine analog compounds
US8709419B2 (en) *	2010-08-17	2014-04-29	Hoffmann-La Roche, Inc.	Combination therapy
US9295669B2 (en)	2010-12-14	2016-03-29	Hoffman La-Roche Inc.	Combination therapy for proliferative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS606348B2 (ja) *	1976-03-31	1985-02-18	三菱化学株式会社	新規ポリアミン類
JPS58135809A (ja) *	1982-02-05	1983-08-12	Fujisawa Pharmaceut Co Ltd	抗炎症・抗リウマチ剤
US4507321A (en) *	1982-02-17	1985-03-26	The Research Foundation Of State University Of New York	Epithelial cell growth regulating composition containing polyamines and a method of using same
JPS606348A (ja) *	1983-06-09	1985-01-14	ケルベル・アクチエンゲゼルシヤフト	回転研削工具の支承装置
NZ212053A (en) *	1984-05-17	1988-02-29	Merrell Dow Pharma	Polyamine containing pharmaceutical compositions for treating neoplasms
US5091576A (en) *	1986-12-02	1992-02-25	University Of Florida	Anti-neoplastic, anti-viral or anti-retroviral spermine derivatives
AU602186B2 (en) *	1987-02-03	1990-10-04	Merrell Dow Pharmaceuticals Inc.	Novel polyamine derivatives
AU628174B2 (en) *	1989-05-23	1992-09-10	Merrell Dow Pharmaceuticals Inc.	A method of potentiating cell-mediated immunity utilizing polyamine derivatives

1994
- 1994-10-25 US US08/329,588 patent/US5516807A/en not_active Expired - Fee Related
1995
- 1995-09-14 AT AT95934421T patent/ATE198706T1/de not_active IP Right Cessation
- 1995-09-14 WO PCT/US1995/011680 patent/WO1996012480A1/en not_active Ceased
- 1995-09-14 DE DE69519937T patent/DE69519937T2/de not_active Expired - Fee Related
- 1995-09-14 DK DK95934421T patent/DK0786991T3/da active
- 1995-09-14 EP EP95934421A patent/EP0786991B1/de not_active Expired - Lifetime
- 1995-09-14 ES ES95934421T patent/ES2155531T3/es not_active Expired - Lifetime
- 1995-09-14 JP JP8513897A patent/JPH10507752A/ja not_active Ceased
- 1995-09-14 MX MX9701838A patent/MX9701838A/es not_active IP Right Cessation
- 1995-09-14 CA CA002198914A patent/CA2198914A1/en not_active Abandoned
- 1995-09-14 PT PT95934421T patent/PT786991E/pt unknown
2001
- 2001-04-06 GR GR20010400577T patent/GR3035725T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
EP0786991A1 (de)	1997-08-06
WO1996012480A1 (en)	1996-05-02
US5516807A (en)	1996-05-14
DE69519937D1 (de)	2001-02-22
CA2198914A1 (en)	1996-05-02
ES2155531T3 (es)	2001-05-16
EP0786991B1 (de)	2001-01-17
PT786991E (pt)	2001-04-30
ATE198706T1 (de)	2001-02-15
GR3035725T3 (en)	2001-07-31
DK0786991T3 (da)	2001-03-19
MX9701838A (es)	1997-06-28
DE69519937T2 (de)	2001-06-07

Legal Events

Date

Code

Title

Description

2006-09-26

A131

Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060926

2007-03-01

A313

Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20070216

2007-03-20

A02

Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070320

Publication	Publication Date	Title
JPH10507752A (ja)	1998-07-28	血管増殖性疾患処置用ポリアミン化合物
US8202860B2 (en)	2012-06-19	Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)
US5643939A (en)	1997-07-01	Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
DE69526934T2 (de)	2003-01-02	Medikamente zur behandlung von restenosis, enthaltend stickstoff freisetzende polymere
JPH0564930B2 (de)	1993-09-16
JP2008525468A (ja)	2008-07-17	ポストコンディショニング臓器保護作用を増強する治療補助薬
EP0612733B1 (de)	1998-09-09	Verwendung von 5-Amino-Phthaloylhydrazid als antihypoxisches und defensives Mittel
HU206186B (en)	1992-09-28	Process for producing pharmaceutical compositions comprising amino acid derivatives having ace-inhibiting effect
JP2012506434A (ja)	2012-03-15	肺動脈高血圧症の治療方法
EP1469853B1 (de)	2008-06-04	Verwendung von 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-d)pyrimidine zur behandlung von harninkontinenz
Knight et al.	1991	Prostacyclin and prostanoid modifiers aid ischemic skin flap survival
JP4568385B2 (ja)	2010-10-27	間歇性跛行改善薬
JP4536258B2 (ja)	2010-09-01	アテローム性動脈硬化症および再狭窄を治療または予防するためのフェニル酢酸組成物
EP1884236B1 (de)	2011-03-02	Ein aminderivat als wirkstoff enthaltender angiogeneseinhibitor
EP0746315A1 (de)	1996-12-11	Verwendung von, und behandlungsverfahren unter verwendung von carbazolyl-(4)-oxypropanolaminverbindungen zur hemmung der proliferation von zellen der glatten muskulatur
US5416120A (en)	1995-05-16	Vascular hypertrophy inhibitor
JPH1179991A (ja)	1999-03-23	移植皮膚又は移植組織の壊死防止剤
TR2024017256A1 (tr)	2026-01-21	Hipertansiyon tedavisinde etkili lipozom formülasyonu.
EP1199078A1 (de)	2002-04-24	Analgetika
US20070254938A1 (en)	2007-11-01	Preventive or Therapeutic Agent for Vascular Intimal Proliferative Disease
JPH05194226A (ja)	1993-08-03	内膜肥厚の予防、治療剤
JPH06157311A (ja)	1994-06-03	血管病変治療剤
JPWO1996005819A1 (ja)	1997-04-28	門脈圧亢進症治療剤
CHEN et al.	2001	Intracoronary adenosine decreases the incidence of no reflow during percutaneous intervention in patients with acute myocardial infarction
JPWO1993003715A1 (ja)	1993-08-05	血管肥厚抑制剤